Benjamin F. Mcgraw III - 05 Nov 2025 Form 3 Insider Report for Evommune, Inc.

Role: Director
Signature: /s/ Gregory S. Moss, Attorney-in-Fact
Issuer symbol: EVMN on NYSE
Transactions as of: 05 Nov 2025
Net transactions value: $0
Form type: 3
Filing time: 05 Nov 2025, 20:07:29 UTC
Previous filing: 21 Nov 2022
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
MCGRAW BENJAMIN F III	Director	C/O EVOMMUNE, INC., 1841 PAGE MILL ROAD, SUITE 100, PALO ALTO	/s/ Gregory S. Moss, Attorney-in-Fact	05 Nov 2025	0001216994

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	EVMN	Stock Option (Right to Buy)							05 Nov 2025	Common Stock	17,609	$1.20	Direct	F1
holding	EVMN	Stock Option (Right to Buy)							05 Nov 2025	Common Stock	61,356	$3.07	Direct	F2
holding	EVMN	Stock Option (Right to Buy)							05 Nov 2025	Common Stock	5,869	$3.84	Direct	F3
holding	EVMN	Stock Option (Right to Buy)							05 Nov 2025	Common Stock	5,869	$1.71	Direct	F4
holding	EVMN	Stock Option (Right to Buy)							05 Nov 2025	Common Stock	8,804	$2.99	Direct	F5

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Immediately exercisable.
F2	One fourth (1/4) of the shares subject to the option award vested on May 11, 2023 and the remaining shares subject to the option vested or shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date.
F3	One fourth (1/4) of the shares subject to the option award vested on May 12, 2024 and the remaining shares subject to the option vested or shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date.
F4	One fourth (1/4) of the shares subject to the option award vested on January 6, 2025 and the remaining shares subject to the option vested or shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date.
F5	One fourth (1/4) of the shares subject to the option award shall vest on December 17, 2025 and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date.